78
Views
2
CrossRef citations to date
0
Altmetric
Review

The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma

Pages 1-8 | Published online: 18 Jan 2012

Figures & data

Figure 1 When an antigen (Ag) is presented in the context of the major histocompatibility complex (MHC) to the T cell receptor (TCR), binding of B7 with CD28 occurs which activates the T cell. Slightly later, the activated T cell stimulates CTLA4 which also binds to B7 to down-regulate the T cell. Ipilimumab inactivates the binding of CTLA4 with B7, allowing the T cell to remain activated.

Abbreviations: Ag, antigen; MHC, major histocompatibility complex; TCR, T cell receptor.

Figure 1 When an antigen (Ag) is presented in the context of the major histocompatibility complex (MHC) to the T cell receptor (TCR), binding of B7 with CD28 occurs which activates the T cell. Slightly later, the activated T cell stimulates CTLA4 which also binds to B7 to down-regulate the T cell. Ipilimumab inactivates the binding of CTLA4 with B7, allowing the T cell to remain activated.Abbreviations: Ag, antigen; MHC, major histocompatibility complex; TCR, T cell receptor.

Table 1 Treatment outcome with diarrhea

Table 2 Immunosuppressive guidelines

Table 3 Doses of immunosuppressive agents